If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


_____ Brought to you by WuXi AppTec _____

Target to Hit Finding: New Methods in Fragment-Based Drug Discovery



  May 12, 2020

  8:00 a.m. PDT, 11:00 a.m. EDT, 16:00 BST, 17:00 CEST




Fragment screening is an excellent method to predict protein druggability. The presentation will discuss the characteristics and advantages of fragment libraries that cover very broad chemical space, enabling high hit rates and the identification of unique binding pockets. Beyond the fragment screening itself, we will look at the importance of employing a full program, which starts with scientific consultation, includes detailed protein engineering, and continues with the comprehensive biophysical hit confirmation. X-ray crystallography or NMR can be used either for fragment screening directly or in later stages for structural hit validation. This structural information is then used for in silico methods and helps to proceed with fragment-to-hit development.

This presentation will look at advanced technologies available for the target-to-hit developmental stage of the drug discovery process. Successful solutions integrate multiple aspects, including target acquisition, hit identification, and comprehensive characterization of hit series, including a dissection of mechanism of action (MoA) by using state-of-the art structural biology approaches. With an ever-increasing number of challenging and often "first-in-the class" targets, we will examine the value of unique workflows ranging from protein engineering to screenings (fragment and DNA encoded library screenings) and beyond to accelerate the drug discovery process.

Brought to you by:


Key Learning Objectives

  • Advantages and limitations of fragment based drug discovery
  • The importance of protein quality and protein construct for the successful screening campaign
  • Fragment-to-hit optimization processes: structure or function enabled

Who Should Attend

  • Biologists
  • Biochemists
  • Medicinal Chemists
  • Pharmacologists Computational Chemists


Dr. habil. Nuska Tschammer
Subject Matter Expert at Crelux,
a WuXi AppTec company


Alexandra Taylor
Associate Editor,